Literature DB >> 22245400

Stenotrophomonas maltophilia--the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study.

Vincent Fihman1, Alban Le Monnier, Stephane Corvec, Francoise Jaureguy, Jacques Tankovic, Hervé Jacquier, Etienne Carbonnelle, Emmanuelle Bille, Marina Illiaquer, Vincent Cattoir, Jean-Ralph Zahar.   

Abstract

OBJECTIVES: Isolation rates of unusual non-fermentative Gram-negative bacilli (i.e. other than Pseudomonas aeruginosa and Acinetobacter baumannii) are increasing but studies are limited to few observations. We aimed at determining risk factors for infection and influence of antibiotic treatment on the outcome.
METHODS: A six-month (December 1, 2008-May 31, 2009) prospective multicenter cohort study was conducted in nine French teaching hospitals. Characteristics of patients colonized or infected by unusual NF-GNB, adequacy of antimicrobial therapies, and outcome were analyzed.
RESULTS: Analysis of 158 patients (median age, 62.7 years) was conducted. Stenotrophomonas maltophilia was the predominant bacterial species isolated (39%) followed by Achromobacter group (15%) and non-baumannii Acinetobacter species (13%). Compared to colonized patients, infected ones were more frequently immunocompromised [relative risk (RR) = 1.63, (95% confidence interval (CI) = 1.02-2.60, P = 0.05)], hospitalized within the last three months [RR 1.67 (95% CI 1.09-2.58, P = 0.02)], admitted in an intensive care unit with central venous catheter [RR 1.74 (95% CI 1.15-2.63, P = 0.01)]. The overall hospital mortality concerned 28 patients (18%) but no association with inadequate antimicrobial treatment was found except in the group of S. maltophilia infected cases [RR 2.81 (95% CI 1.01-7.83, P = 0.02)].
CONCLUSION: Naturally carbapenems-resistant S. maltophilia is the main unusual NF-GNB pathogen in hospitalized patients, leading to inappropriate empirical antibiotic treatment at the time of emerging extended-spectrum β-lactamase-producing bacteria.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245400     DOI: 10.1016/j.jinf.2012.01.001

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  19 in total

1.  Clinical characteristics and outcomes of patients with pleural infections due to Stenotrophomonas maltophilia at a medical center in Taiwan, 2004-2012.

Authors:  M-R Lee; H-C Wang; C-Y Yang; C-K Lin; H-Y Kuo; J-C Ko; W-H Sheng; L-N Lee; C-J Yu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-24       Impact factor: 3.267

2.  Characterization of maltocin P28, a novel phage tail-like bacteriocin from Stenotrophomonas maltophilia.

Authors:  Jian Liu; Peng Chen; Congyi Zheng; Yu-Ping Huang
Journal:  Appl Environ Microbiol       Date:  2013-07-08       Impact factor: 4.792

3.  Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient.

Authors:  Maria F Mojica; Christopher P Ouellette; Amy Leber; M Brian Becknell; Monica I Ardura; Federico Perez; Masako Shimamura; Robert A Bonomo; Samuel L Aitken; Samuel A Shelburne
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli.

Authors:  Rodrigo E Mendes; M R K Alley; Helio S Sader; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

5.  Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia.

Authors:  B Lakatos; B Jakopp; A Widmer; R Frei; H Pargger; L Elzi; M Battegay
Journal:  Infection       Date:  2014-03-14       Impact factor: 3.553

6.  Risk Factors Associated with Stenotrophomonas maltophilia Bacteremia: A Matched Case-Control Study.

Authors:  Kosuke Sumida; Yong Chong; Noriko Miyake; Tomohiko Akahoshi; Mitsuhiro Yasuda; Nobuyuki Shimono; Shinji Shimoda; Yoshihiko Maehara; Koichi Akashi
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

7.  Clinical factors associated with acquisition of resistance to levofloxacin in Stenotrophomonas maltophilia.

Authors:  Ji Hyeon Baek; Chang Oh Kim; Su Jin Jeong; Nam Soo Ku; Sang Hoon Han; Jun Yong Choi; Dongeun Yong; Young Goo Song; Kyungwon Lee; June Myung Kim
Journal:  Yonsei Med J       Date:  2014-07       Impact factor: 2.759

Review 8.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

9.  Phylogenetic analysis of Stenotrophomonas spp. isolates contributes to the identification of nosocomial and community-acquired infections.

Authors:  Vinicius Godoy Cerezer; Silvia Yumi Bando; Jacyr Pasternak; Marcia Regina Franzolin; Carlos Alberto Moreira-Filho
Journal:  Biomed Res Int       Date:  2014-04-10       Impact factor: 3.411

10.  A Patient Presenting with Cholangitis due to Stenotrophomonas Maltophilia and Pseudomonas Aeruginosa Successfully Treated with Intrabiliary Colistine.

Authors:  Pablo N Pérez; María A Ramírez; José A Fernández; Laura Ladrón de Guevara
Journal:  Infect Dis Rep       Date:  2014-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.